Comerica Bank’s Mineralys Therapeutics MLYS Stock Holding History

Comerica Bank’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$28.3K	Buy	781 +1	+0.1%	+$40	﹤0.01%	3017
2025 Q3	$29.6K	Sell	780 -23	-3%	-$497	﹤0.01%	3003
2025 Q2	$10.9K	Buy	803 +206	+35%	+$2.98K	﹤0.01%	3189
2025 Q1	$9.48K	Sell	597 -47	-7%	-$541	﹤0.01%	3189
2024 Q4	$7.93K	Hold	644	–	–	﹤0.01%	3223
2024 Q3	$7.8K	Hold	644	–	–	﹤0.01%	3233
2024 Q2	$7.54K	Sell	644 -46	-7%	-$579	﹤0.01%	3221
2024 Q1	$8.91K	Hold	690	–	–	﹤0.01%	3206
2023 Q4	$5.93K	Buy	690 +177	+35%	+$1.39K	﹤0.01%	3275
2023 Q3	$4.88K	Buy	+513	New	+$6.69K	﹤0.01%	3368

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Comerica Bank's MLYS Position: Q4 2025 in Review

Comerica Bank increased its Mineralys Therapeutics (MLYS) stake by 0.13% in Q4 2025, buying an estimated $40 and bringing the position to 781 shares worth $28.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3017.

Comerica Bank first reported a position in MLYS in Q3 2023 and has held it in 10 quarters since. The position peaked at $29.6K in Q3 2025. 223 funds tracked by Wall St. Rank hold MLYS as of Q4 2025.

Comerica Bank held 781 shares of Mineralys Therapeutics worth $28.3K as of Q4 2025.
Comerica Bank bought 1 Mineralys Therapeutics share in Q4 2025, an estimated $40.
Mineralys Therapeutics made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3017 holding.
Comerica Bank first reported a position in Mineralys Therapeutics in Q3 2023 and has held it in 10 quarters since.
Comerica Bank's Mineralys Therapeutics position peaked at $29.6K in Q3 2025.
223 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.